Gene Therapy on Cardiovascular Disease Market Size, Share & Trends Analysis Report By Type (Viral Gene Therapy, Non-Viral Gene Therapy), By Application (Heart Disease, Vascular Disease), By Region, And By Segment Forecasts, 2024-2031.

Chapter 1. Methodology and Scope 1.1. Research Methodology 1.2. Research Scope & Assumptions Chapter 2. Executive Summary Chapter 3. Global Gene Therapy on Cardiovascular Disease Market Snapshot Chapter 4. Global Gene Therapy on Cardiovascular Disease Market Variables, Trends & Scope 4.1. Market Segmentation & Scope 4.2. Drivers 4.3. Challenges 4.4. Trends 4.5. Investment and Funding Analysis 4.6. Industry Analysis – Porter's Five Forces Analysis 4.7. Competitive Landscape & Market Share Analysis 4.8. Impact of Covid-19 Analysis Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis 5.1. by Type & Market Share, 2019 & 2031 5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type: 5.2.1. Viral Gene Therapy 5.2.2. Non-Viral Gene Therapy Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis 6.1. by Application & Market Share, 2019 & 2031 6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application: 6.2.1. Heart Disease 6.2.2. Vascular Disease Chapter 7. Gene Therapy on Cardiovascular Disease Market Segmentation 3: Regional Estimates & Trend Analysis 7.1. North America 7.1.1. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 7.1.2. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031 7.1.3. North America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 7.2. Europe 7.2.1. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 7.2.2. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031 7.2.3. Europe Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 7.3. Asia Pacific 7.3.1. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 7.3.2. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031 7.3.3. Asia Pacific Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 7.4. Latin America 7.4.1. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 7.4.2. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031 7.4.3. Latin America Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 7.5. Middle East & Africa 7.5.1. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Type, 2019-2031 7.5.2. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by Application, 2019-2031 7.5.3. Middle East & Africa Gene Therapy on Cardiovascular Disease Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031 Chapter 8. Competitive Landscape 8.1. Major Mergers and Acquisitions/Strategic Alliances 8.2. Company Profiles 8.2.1. Biogen 8.2.2. Novartis 8.2.3. Gilead Sciences 8.2.4. Sarepta Therapeutics 8.2.5. Alnylam Pharmaceuticals 8.2.6. Amgen 8.2.7. Spark Therapeutics 8.2.8. Akcea Therapeutics 8.2.9. Sunway Biotech 8.2.10. bluebird bio 8.2.11. SIBIONO 8.2.12. AnGes 8.2.13. Orchard Therapeutics 8.2.14. Other Market Players